16:59 , Jun 18, 2019 |  BC Innovations  |  Distillery Therapeutics

APLN17 analog identified for abdominal aortic aneurysm

DISEASE CATEGORY: Cardiovascular INDICATION: Aneurysm An analog of APLN17 could help treat abdominal aortic aneurysm (AAA). Levels of APLN, which is processed into APLN17 and other APLN peptides, were higher in diseased aorta from AAA...
23:50 , Jun 14, 2019 |  BC Extra  |  Clinical News

June 14 Clinical Quick Takes: Chi-Med, BeiGene, UCB, Global Blood and more

Chi-Med’s surufatinib meets in Phase III for extra-pancreatic neuroendocrine tumors  Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said it is planning a pre-NDA meeting with China’s National Medical Products Administration (NMPA) after surufatinib (formerly sulfatinib) met...
19:49 , Jun 7, 2019 |  BioCentury  |  Emerging Company Profile

insitro: machine learning with designated data

Just 12 months after announcing the launch of insitro, AI veteran and CEO Daphne Koller has led the drug discovery and machine learning company to a series A round of over $100 million and a...
23:52 , May 30, 2019 |  BC Innovations  |  Emerging Company Profile

Aro delivers bispecifics, siRNAs where others can’t

A year after its launch, Susan Dillon and Karyn O’Neil’s Aro has begun to reveal details about how the J&J spinout’s Centyrins could form small bispecifics and stable siRNA therapies to penetrate hard-to-reach cancers. Therapies...
00:21 , May 3, 2019 |  BC Innovations  |  Product Development

With a deal and a debut, targeted oligo delivery gets a boost from ADCs

The marriage of antibody-drug conjugates and oligonucleotides won two votes of confidence last month with a deal between Lilly and Avidity, and the debut of Atlas-backed Dyne Therapeutics. The approach promises delivery of oligos to...
19:53 , May 2, 2019 |  BC Extra  |  Company News

CStone adds trispecific antibody to pipeline with Numab deal

CStone will provide early stage R&D funding in exchange for exclusive, Asian rights to develop and commercialize preclinical trispecific antibody ND021 from Numab. The immunotherapy, which targets PD-L1, 4-1BB and human serum albumin, would be...
20:15 , May 1, 2019 |  BC Extra  |  Preclinical News

Ionis' methyl modification could reduce ASO toxicity

Ionis thinks a single methyl modification could reduce hepatoxicity of highly potent antisense oligonucleotides, expanding the opportunities for their development. In a paper published Monday in Nature Biotechnology , Ionis Pharmaceuticals Inc. (NASDAQ:IONS) researchers sought...
21:59 , Apr 25, 2019 |  BC Extra  |  Company News

Salix licenses S1P receptor modulator from Mitsubishi

Mitsubishi has found a new partner for its oral S1P receptor modulator in Salix, two years after Biogen decided to return its rights to the compound. Salix Pharmaceuticals Ltd. gained exclusive rights Thursday to develop...
10:32 , Apr 22, 2019 |  BC Extra  |  Company News

Lilly pays $35M up front to partner with Avidity on oligo conjugates

Lilly partnered with Avidity to develop antibody-oligonucleotide conjugates to treat immune diseases, with the biotech receiving $20 million up front and a $15 million investment. Avidity Biosciences LLC (La Jolla, Calif.) is eligible to receive...
20:44 , Apr 18, 2019 |  BC Extra  |  Clinical News

FDA draft guidance suggests comparing bispecifics to monospecific antibodies

Demonstrated efficacy of a bispecific antibody against monospecific products targeting the different antigens could be a requirement for gaining FDA approval, according to draft guidance released Thursday. The guidance describes non-clinical and clinical recommendations for...